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  19 
ABSTRACT 20 
 21 
Purpose Fluoroquinolone resistance (FQ-r) in extended-spectrum β-lactamase 22 
(ESBL) producers is an urgent health concern in countries where ESBL-producing K. 23 
pneumoniae (ESBL-Kpn) is prevalent. We investigated FQ-r in Japan where ESBL-Kpn is 24 
less prevalent  25 
Methodology Clinical ESBL-Kpn isolates from 2011 to 2013 were collected in Nagasaki 26 
University Hospital. The ESBL genotypes included CTX-M-15, and the mechanisms of FQ-r 27 
through plasmid-mediated quinolone resistance (PMQR) and mutations in quinolone 28 
resistance-determining regions (QRDRs) were examined. Clonality was analyzed by 29 
enterobacterial repetitive intergenic consensus (ERIC)-PCR and multi-locus sequence 30 
typing was performed on selected isolates.  31 
Results Thirty ESBL-Kpn isolates, including 7 levofloxacin-resistant isolates, were 32 
obtained from different patients. An increase in CTX-M-15-producing strains was observed 33 
during the study period (0/11 in 2011, 3/8 in 2012, and 5/11 in 2013). PMQR was detected in 34 
53.3% of the isolates and aac-(6’)-Ib-cr was the most common (36.7%). ST15 was observed 35 
in 60.0% of the isolates, and for the most predominant ERIC-PCR profiles, 62.5% of the 36 
isolates possessed the CTX-M-15 genotype and 71.4% were levofloxacin-resistant. 37 
Levofloxacin-resistance was significantly more common in CTX-M-15 isolates (62.5%) 38 
compared to non-CTX-M-15 isolates (9.1%). Three QRDR mutations and aac(6’)-Ib-cr, but 39 
not qnrB and qnrS, were significantly enriched in the CTX-M-15 isolates (100.0%) compared 40 
to the non-CTX-M-15 isolates (13.6%).  41 
Conclusion Cumulatively, these results indicate that the epidemic strain, the 42 
CTX-M-15-producing K. pneumoniae ST15, is covertly spreading even when 43 
ESBL-producers are not prevalent. Monitoring these epidemic strains and ESBLs in general 44 
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INTRODUCTION 54 
 55 
Extended-spectrum β-lactamases (ESBLs) are enzymes produced mainly by the 56 
Enterobacteriaceae family. The genes encoding ESBL can be transmitted via plasmids, and 57 
the expansion of ESBL-producing microbes is a global concern. Klebsiella pneumoniae is a 58 
major ESBL-producing pathogen, as well as Escherichia coli. K. pneumoniae causes severe 59 
infections, such as pneumonia, urinary tract infections, and sepsis. The worldwide 60 
prevalence of ESBL-producing K. pneumoniae (ESBL-Kpn) has dramatically increased 61 
since the description of this resistance in the early 1980s. However, there are some 62 
variations in both the prevalence and predominant ESBL genes found in strains of K. 63 
pneumoniae in different countries [1].  64 
Specific ESBL-encoding genes and clones are involved in the global dissemination 65 
of ESBL. Classically, SHV and TEM were major ESBL-encoding genes. However, CTX-M 66 
genes, including the CTX-M-1, CTX-M-2, and CTX-M-9 groups, have become more 67 
common ESBL genes associated with E. coli and K. pneumoniae [1]. In particular, 68 
CTX-M-15, a CTX-M-1 group of ESBLs, has been recognized as an epidemic-related ESBL. 69 
Of note, most CTX-M-15-producing E. coli belong to a clone called ST131, and these are 70 
closely associated with fluoroquinolone resistance (FQ-r) [2]. CTX-M-15 has also been 71 
found in K. pneumoniae, and may be sporadically associated with multi-drug resistance and 72 
some specific sequence types of bacteria [3, 4]. Furthermore, the relationship between 73 
CTX-M-15 and FQ-r is not well understood.  74 
Fluoroquinolones are alternative antibiotics for patients with ESBL-Kpn infections. 75 
Fluoroquinolones target DNA gyrase and topoisomerase IV, which are encoded by gyrA and 76 
parC, respectively. Two mechanisms for quinolone resistance are the acquisition of 77 
plasmid-mediated quinolone resistance (PMQR) genes (such as aac(6’)-Ib-cr and qnr) and 78 
spontaneous mutations in the quinolone resistance-determining regions (QRDRs) of the 79 
gyrA and parC genes. Acquisition of qnr or aac(6’)-Ib-cr genes can reduce susceptibility to 80 
fluoroquinolone by protecting DNA gyrase from the drug’s effects or by triggering 81 
N-acetylation of piperazinyl amine residues [5], respectively. K. pneumoniae is normally 82 
highly sensitive to quinolone antibiotics; however, quinolone-resistant ESBL producers are 83 
emerging through these aforementioned mechanisms [6-8].  84 
In the United States and many European and Asian countries (except Japan), more 85 
than 20% of K. pneumoniae strains were found to be ESBL-positive [9]. In contrast, Japan 86 
had a low prevalence [10, 11], and our previous study conducted in a Japanese tertiary 87 
hospital revealed that while ESBL-Kpn constituted only 2.8% of clinical isolates, they are on 88 
the rise [12]. Similarly, 4-5% of K. pneumoniae identified in Canada and Australia were ESBL 89 
producers [9]. For countries with a low prevalence of ESBL-Kpn, monitoring these strains 90 
and subsequent FQ-r is critical for controlling current and future infections. Therefore, we 91 
studied phenotypically-identified ESBL-Kpn in microbiology laboratory of our hospital, 92 
focusing on CTX-M-15 isolates and their resistance to fluoroquinolone.  93 
 94 
MATERIALS AND METHODS 95 
 96 
Collection of clinical isolates 97 
This study was conducted at Nagasaki University Hospital, which is a tertiary 98 
hospital with 861 beds. Hospital microbiology laboratory databases from 2011 to 2013 were 99 
reviewed, and clinical isolates of K. pneumoniae were analyzed for bacteriological and 100 
molecular epidemiology. The identification, antimicrobial susceptibilities and ESBL 101 
production were examined using BD PhoenixTM Automated Microbiology System (BD 102 
Diagnostic Systems, Sparks, MD), as described previously [12]. The MIC values of 103 
levofloxacin, cefotaxime and gentamicin were determined according to the Clinical and 104 
Laboratory Standards Institute M100-S23 [13]. FQ-r was determined using the MIC values of 105 
levofloxacin because the MIC of levofloxacin was routinely measured throughout the study 106 
period. The number of phenotypically-identified ESBL-Kpn in 2011, 2012, and 2013 was 11, 107 
8, and 11, respectively. 108 
 109 
 110 
Extraction of plasmids and DNA 111 
All isolates from patients had been preserved through a freeze-drying process. We 112 
re-cultured all ESBL-Kpn isolates obtained from 2011 to 2013. Plasmids were extracted 113 
using a boiling method [12]. Briefly, a few colonies were suspended in 1000 μL of Tris-EDTA 114 
buffer (pH 8.0), boiled for 10 min, and subsequently centrifuged for 5 min at 12000 rpm. The 115 
supernatant containing each plasmid was transferred to a new tube. For total DNA extraction, 116 
the DNeasy Blood & Tissue Kit (QIAGEN, Hilden, Germany) was used according to the 117 
manufacturer’s instructions.  118 
 119 
Genotyping of ESBL 120 
PCR genotyping of ESBL plasmids was performed using 6 sets of previously 121 
published primers to amplify type-specific ESBL genes, including those of the CTX-M-1, 122 
CTX-M-2, CTX-M-9, TEM, SHV groups, and CTX-M-15 [14, 15]. PCR thermal cycling 123 
conditions were as follows: 1 cycle of 95°C for 10 min; 30 cycles of 95°C for 40 sec, 60°C for 124 
40 sec, and 72°C for 1 min; and 1 cycle of 72°C for 7 min. The PCR products were run on a 125 
2% agarose gel and visualized by staining with ethidium bromide. 126 
 127 
Screening for qnr and aac(6’)-Ib-cr genes 128 
PMQRs including qnrA, qnrB, qnrS, and aac(6’)-Ib-cr were detected, as previously 129 
reported [16]. Briefly, qnr genes were amplified using multiplex PCR, and aac(6’)-Ib-cr was 130 
distinguished from aac(6’)-Ib using pyrosequencing to discern two single-nucleotide 131 
polymorphisms [17]. PCR products of all PMQR genes were kindly obtained from Dr. K. 132 
Tateda and used as positive controls. 133 
 134 
Pyrosequencing of QRDRs 135 
 Mutations in the QRDRs of gyrA and parC were analyzed by pyrosequencing. 136 
Primers were designed using the PyroMark Assay Design software 2.0 (Qiagen, Hilden, 137 
Germany) on the basis of sequence information available (GenBank accession number 138 
AF052258 and AF303641). The predicted amplicons contained major mutation sites in the 139 
QRDRs of gyrA (Ser83 and Asp87) and parC (Ser80 and Glu84) [18] (Table 1). The target 140 
genes were amplified by PCR using Amplitaq Gold 360 Master Mix (Applied Biosystems) 141 
with the following PCR thermal cycling conditions: 1 cycle of 95°C for 5 min; 50 cycles of 142 
95°C for 15 sec, 67°C for 30 sec, 72°C for 15 sec; and 1 cycle of 72°C for 5 min. The PCR 143 
products were sequenced using PyroMark Q96 ID (Qiagen) and PyroMark Gold Q96 144 
Reagents (Qiagen).  145 
 146 
Analyses of clonality 147 
Clonal relationships were assessed by enterobacterial repetitive intergenic 148 
consensus-PCR (ERIC-PCR) [19]. We used previously published primers to amplify ERIC 149 
sequences. PCR thermal cycling conditions were as follows: 1 cycle of 95°C for 5 min; 40 150 
cycles of 94°C for 1 min, 52°C for 1 min, 72°C for 2 min; and 1 cycle of 72°C for 10 min. The 151 
PCR products were analyzed using the Microchip Electrophoresis System for DNA/RNA 152 
analysis MCE®-202 MultiNA (Shimadzu, Kyoto, Japan). Fingerprints on electropherogram 153 
were compared visually and isolates having at least one different peak were classified as 154 
different ERIC profile. 155 
Multi-locus sequence typing (MLST) was performed using seven conserved 156 
housekeeping genes (rpoB, gapA, mdh, pgi, phoE, infB, and tonB) [20] for selected isolates 157 
which have specific characteristics such as CTX-M-15-positive, levofloxacin-resistant or 158 
belonging to the most dominant ERIC profile. PCR amplification and sequencing were 159 
performed by following Pasteur Institute protocol. 160 
(http://bigsdb.pasteur.fr/klebsiella/primers_used.html). The sequence type was assigned 161 
based upon the MLST database (http://bigsdb.web.pasteur.fr/index.html). 162 
 163 
Statistical analysis 164 
Statistical analyses were performed using GraphPad Prism (GraphPad Prism 165 
Software Inc., CA). A χ2 test was used to assess statistical differences among the 166 




Molecular profiles of β-lactamases in phenotypically identified ESBL-Kpn  171 
 There were 30 phenotypically identified ESBL-Kpn isolates (Table 2). Of the 30 172 
isolates, 29 (96.7%) were positive for one or more ESBL genes. The number of isolates 173 
possessing one, two, or three ESBL genes was 11 (36.7%), 14 (46.6%), and 4 (13.3%), 174 
respectively. The most prevalent ESBL gene was SHV (n=24, 80.0%), followed by CTX-M-1 175 
(n=11, 36.7%), TEM (n=8, 26.7%), CTX-M-2 (n=5, 16.7%), and CTX-M-9 (n=3, 10.0%). Of 176 
the CTX-M-1-positive isolates (n=11), CTX-M-15-positive isolates (n=8) accounted for 177 
72.7%. The frequency of CTX-M-15-positive isolates gradually increased from 2011 to 2012 178 
and 2013 (0.0%, 37.5%, and 45.5%, respectively). 179 
 180 
Antimicrobial susceptibility test 181 
In these phenotypically-identified ESBL-Kpn isolates, 7 (23.3%) were 182 
levofloxacin-resistant (MIC≥8 μg/mL) (Table3). The number of cefotaxime- and gentamicin- 183 
resistant isolates was 22 (73.3%), and 7 (23.3%), respectively (Table3). Only one isolate 184 
showed resistance in both gentamicin and levofloxacin. 185 
 186 
Analysis of PMQRs and QRDRs 187 
Fluoroquinolone-resistant genes were analyzed in all of the isolates (Table 3).  188 
PMQRs were detected in 16 isolates (53.3%). The most common PMQR was 189 
aac(6’)-Ib-cr (n=11), followed by qnrS (n=5) and qnrB (n=4). Strains containing qnrA were 190 
not obtained. Levofloxacin-resistant isolates frequently possessed aac(6’)-Ib-cr. This was 191 
also observed for levofloxacin-non-resistant isolates, but the prevalence was significantly 192 
higher in the levofloxacin-resistant isolates (85.7% versus 21.7%; p<0.01). All nine isolates 193 
carrying qnr (qnrS, n=5; qnrB, n=4) were levofloxacin-non-resistant. 194 
Chromosomal mutations in QRDRs were observed in 12 isolates (40.0%). All seven 195 
levofloxacin-resistant isolates had three mutations each in QRDRs. The most prevalent 196 
amino acid substitutions were Ser83Phe and Asp87Ala in gyrA, in addition to Ser80Ile in 197 
parC (n=6). The rest of the fluoroquinolone-resistant isolates displayed Ser83Phe and 198 
Asp87Asn substitutions in gyrA, in addition to Glu84Lys in parC. The isolate for which the 199 
levofloxacin MIC was 4.0 μg/mL displayed a Ser83Tyr change in gyrA. However, all five 200 
isolates possessing single QRDR mutations were not phenotypically resistant to 201 
levofloxacin. 202 
 203 
Clonality analysis of the ESBL-Kpn 204 
All ESBL-Kpn isolates were screened using ERIC-PCR for clonality analysis (Table 205 
3 and Figure 1). ERIC-PCR categorized 30 strains into 18 groups. The most dominant 206 
ERIC-PCR profile was named E1, and 10 isolates (33.3%) belonged to this profile. In the E1 207 
profile, five isolates (50%) were positive for CTX-M-15 while three isolates (13.6%) 208 
possessed a non-E1 profile. Of the 30 strains, a total of seven levofloxacin-resistant isolates 209 
belonged to the profile E1, and no isolates with levofloxacin resistance were detected in the 210 
other ERIC-PCR profiles. 211 
To screen sequence types, MLST was performed on isolates that had been 212 
classified as CTX-M-15-positive or levofloxacin-resistant. MLST was also performed on 213 
isolates that displayed a profile E1 based upon ERIC-PCR. Among the selected isolates, 214 
ST15 was most commonly observed (n=6), followed by ST551 (n=2), ST252 (n=1), and 215 
ST1035 (n=1). ST15 was observed primarily in isolates that displayed an ERIC-PCR profile 216 
E1 (6/10, 60%), CTX-M-15-positive genotype (5/8, 62.5%), and levofloxacin resistance (5/7, 217 
71.4%).  218 
 219 
Relationship between CTX-M-15 and quinolone-resistant genes 220 
Quinolone-resistant genes were compared between isolates possessing CTX-M-15 221 
versus those lacking CTX-M-15 (Table 4). Levofloxacin resistance was observed in 62.5% of 222 
the isolates positive for CTX-M-15, whereas only 9.1% of the non-CTX-M-15 isolates 223 
displayed levofloxacin resistance (p<0.01). The presence of three QRDR mutations was 224 
also more frequent in CTX-M-15-positive isolates compared to the non-CTX-M-15 isolates 225 
(62.5% vs. 9.1%, p<0.01). For PMQRs, the percentage of isolates possessing aac(6’)-Ib-cr 226 
was 100.0% in the CTX-M-15-positive isolates and 13.6% in the non-CTX-M-15 isolates 227 
(p<0.01). In contrast, the prevalence of qnrB and qnrS was not significantly different 228 




In European countries, the predominant β-lactamase in ESBL-Kpn has dramatically 233 
shifted from SHV and TEM to the CTX-M-type. The CTX-M-1 group has been rapidly 234 
expanding, and it is now the predominant ESBL-Kpn group found in European countries [21]. 235 
In particular, CTX-M-15, a CTX-M-1 group ESBL, has been recognized as a pandemic ESBL 236 
gene in the Enterobacteriaceae family [2]. However, the number of ESBL isolates and the 237 
composition of ESBL genes can vary geographically. The CTX-M-1 group has been 238 
historically less prevalent in Japan, where the CTX-M-2 group dominated as the CTX-M-type 239 
ESBL before 2000 [21]. We previously reported on the epidemiology of clinical ESBL-Kpn 240 
isolates in our hospital from 2006 to 2010, and discovered an increase in ESBL-producers in 241 
clinical isolates of both K. pneumoniae and E. coli [12]. Thus, the present study was 242 
performed as a follow-up focusing on K. pneumoniae.  243 
Compared to our previous study [12], the proportions of SHV isolates in the 244 
ESBL-Kpn population did not change (the percentages of ESBL-type SHV were 80.0% in 245 
both studies). However, the percentages of CTX-M-1-positive isolates dramatically 246 
increased from 5.0% to 36.7%. This was mainly due to the increase in CTX-M-15 isolates 247 
overall. CTX-M-15 was not previously prevalent in Japan [12, 22]. However, in other Asian 248 
countries, it reportedly constituted 59.8% of the ESBL-Kpn isolates that caused 249 
hospital-acquired pneumonia [23]. In the present study, the shift from non-CTX-M-15 to 250 
CTX-M-15 isolates was observed even though the total number of isolates was similar for 251 
each year studied. Most of the isolates possessing CTX-M-15 also had one or more other 252 
β-lactamases, implying that CTX-M-15 has the potential to coexist with other β-lactamases 253 
and it might also be acquired by ESBL strains because SHV and TEM typically dominate the 254 
population. Conversely, the expansion of CTX-M-15 in K. pneumoniae could be restrictive 255 
among conventional ESBL producers in Japan.  256 
In the present study, PMQRs were observed in 53.3% of the ESBL-Kpn isolates, 257 
and aac(6')-Ib-cr, qnrB, and qnrS genes were detected in 36.7%, 13.3%, and 16.7% of these 258 
strains, respectively. Compared to a previous report of cephalosporin-resistant K. 259 
pneumoniae isolates in Japan [24], the prevalence of PMQRs was similar (66.7%), but the 260 
percentages for each PMQR gene in the total population were different (aac(6')-Ib-cr, 4.2%; 261 
qnrB, 50.0%; qnrS, 16.7%). These findings suggest that local factors, such as study region 262 
and study population, can affect PMQR composition. PMQRs might be more commonly 263 
observed in K. pneumoniae than in E. coli [6, 24]. It is reported that aac(6’)-Ib-cr has 264 
epidemiologically strong associations with CTX-M-15 [8]. Qnr genes are also relevant to 265 
SHV or CTX-M-9, but qnr genes do not lead to significant increases in fluoroquinolone MICs 266 
[6]. Thus, the present data are compatible with these earlier findings. As shown in our study, 267 
PMQRs can elevate the fluoroquinolone MIC, but their effects are mild. Importantly, these 268 
strains could still be recognized as sensitive in clinical settings. However, considering that K. 269 
pneumoniae is highly sensitive to fluoroquinolones (0.25 μg/mL in MIC90) [25], the isolates 270 
that have a levofloxacin MIC of 1.0 μg/mL are not clinically negligible. Therefore, we should 271 
continue to monitor PMQRs in K. pneumoniae, and further studies are needed to assess the 272 
clinical impact of these PMQR-possessing strains. 273 
Compared to PMQRs, QRDR mutations can dramatically elevate MIC values for 274 
fluoroquinolone. Generally, more than one double mutation in QRDRs causes high FQ-r [26]. 275 
Consistent with this report, all the isolates with three QRDR mutations were 276 
fluoroquinolone-resistant. The triplet QRDR mutations (Ser83Phe, Asp87Ala, and Ser80Ile; 277 
Ser83Phe, Asp87Asn, and Glu84Lys) in the present study have been commonly observed 278 
among fluoroquinolone-resistant K. pneumoniae [27, 28]. The effect of the Ser83Tyr 279 
substitution in GyrA on fluoroquinolone susceptibility is controversial. One study 280 
demonstrated that the Ser83Tyr change mildly elevated the ciprofloxacin MIC value [4], 281 
while another report found that it did not affect fluoroquinolone susceptibility [29].  282 
In a study conducted in nine Asian countries excluding Japan, CTX-M-15 isolates 283 
belonged to 25 different STs. However, ST11, ST15, and ST340 were the predominant STs 284 
identified [23]. In the present study, ST15 was most commonly observed in the CTX-M-15 285 
isolates (62.5%). It is reported that the incidence of ST15 among CTX-M-15-positive K. 286 
pneumoniae was 57.1% in Portugal [30] and 27.3% in the U.S. [31], while ST15 was not 287 
reported in Spain [4]. In the present study, 5/7 (71.4%) fluoroquinolone-resistant isolates 288 
from different patients displayed the same molecular signature, including ST15, aac(6’)-Ib-cr, 289 
three QRDR mutations, and CTX-M-15. The same profile has been identified in an epidemic 290 
clone in Hungary [28]. This suggests that the ST15 ESBL-Kpn clone is expanding, and might 291 
gradually spread in Japan. Although MLST was not performed for all the isolates, the ST15 292 
strain could have some discrete characteristics that make it especially virulent, such as a 293 
tendency to obtain mutations in QRDRs and synergize with CTX-M-15 strains. It seems 294 
difficult to conclude all ST15 isolates resulted from a local outbreak because these isolates, 295 
except the isolate no.2 and no.3, have various backgrounds in isolated date and location.  296 
There are some limitations to our study. First, our study does not include Kpn 297 
strains which have ESBL genes but are negative for phenotype-based ESBL-detection. 298 
Some SHV/TEM variants or ESBL genes co-harboring with plasmid-mediated AmpC 299 
β-lactamase can be missed by phenotype-based ESBL-detection {Canton, 2008 #1094}. 300 
Therefore, we could not know about the relationship between these undiagnosed ESBL 301 
genes and fluoroquinolone-resistance. Second, because it focused on a single hospital, the 302 
number of specimens was small and we could not evaluate the differences among facilities. 303 
Furthermore, the clinical backgrounds of patients who had contracted the epidemic clone 304 
could not be collected. Therefore, the risk factors and the suspected routes of transmission 305 
of this strain are still unknown. Lastly, ST15 was commonly observed in 306 
fluoroquinolone-resistant isolates, but MLST was performed only in the selected isolates.  307 
In conclusion, our study suggests that CTX-M-15-producing K. pneumoniae ST15 is 308 
a global pandemic clone currently emerging in Japan. This clone might be spreading even if 309 
ESBL-producers are not prevalent. Thus, it is important to monitor epidemic clones and 310 
ESBLs in countries where ESBL-producers are not prevalent, as opposed to focusing only 311 
on countries currently experiencing epidemics. To mitigate the spread of these 312 
fluoroquinolone-resistant strains, antimicrobial stewardship should be strongly encouraged 313 
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  428 
Figure 1. ERIC profile of ESBL-producing K. pneumoniae. 429 
Electrophoresis patterns were categorized into 18 groups after analysis of PCR 430 
products by capillary electrophoresis. Each lane numbers corresponds to the numbers in 431 
Table 3. The image was edited to be in order of indicated number using original data. M, 432 
marker. UM, upper marker. LM, lower marker. 433 
 434 
  435 
Table 1. Primers for pyrosequencing 436 
 437 
Primer name Primer sequence (5'→3') 
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2011 2012 2013 
Isolates with CTX­M­15     
CTX­M­1 (CTX­M­15) 0 0 1 1 
CTX­M­1 (CTX­M­15), SHV 0 0 3 3 
CTX­M­1 (CTX­M­15), TEM 0 1 0 1 
CTX­M­1 (CTX­M­15), TEM, SHV 0 2 1 3 
Subtotal, n (% in the year(s)) 0 (0.0) 3 (37.5) 5 (45.5) 8 (26.7) 
Isolates without CTX­M­15     
CTX­M­1 (non­CTX­M­15), SHV 0 1 2 3 
CTX­M­2, SHV 4 0 0 4 
CTX­M­2, TEM, SHV 1 0 0 1 
CTX­M­9 1 0 0 1 
CTX­M­9, TEM 1 0 1 2 
SHV 4 2 3 9 
TEM, SHV 0 1 0 1 
Subtotal, n (% in the year(s)) 
11 
(100.0) 
4 (50.0) 6 (54.5) 21 (70.0)
Not detected, n (% in the year(s)) 0 (0.0) 1 (12.5) 0 (0.0) 1 (3.3) 
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Ser83 Asp87 Ser80 Glu84 CTX GEN LVX 
1 EK1302 04/13 General ICU Sputum ST15 E1 Ib-cr - Phe Ala Ile WT CTX-M-15 ≥64 ≤2 ≥8 
2 EK1304 08/13 Cardiology Sputum ST15 E1 Ib-cr - Phe Ala Ile WT
SHV, 
CTX-M-15 
≥64 ≤2 ≥8 
3 EK1305 08/13 General ICU 
Tracheal 
aspirate 
ST15 E1 Ib-cr - Phe Ala Ile WT
SHV, 
CTX-M-15 
≥64 ≤2 ≥8 
4 EK1307 09/13 Hematology 
Throat 
swab 
ST15 E1 Ib-cr - Phe Ala Ile WT
SHV, TEM, 
CTX-M-15 
≥64 ≥16 ≥8 
5 EK1311 11/13 Thoracic surgery 
Surgical 
wound 
ST15 E1 Ib-cr - Phe Ala Ile WT
SHV, 
CTX-M-15 
≥64 ≤2 ≥8 
6 EK1105 04/11 Hematology Feces ST15 E1 - - WT WT WT WT CTX-M-9 ≥64 ≥16 ≤0.5 
7 EK1207 11/12 Pulmonology Urine ST252 E1 - - Phe Asn WT Lys
SHV, CTX-M-1 
(non-CTX-M-15)
≥64 ≤2 ≥8 
8 EK1201 01/12 Otorhinolaryngology Sputum ST551 E2 Ib-cr - WT WT WT WT
TEM, SHV, 
CTX-M-15 
≥64 ≥16 ≤0.5 
9 EK1110 10/11 Pediatrics Urine ST551 E1 Ib-cr - Phe Ala Ile WT SHV ≤1 ≤2 ≥8 
10 EK1204 08/12 Digestive surgery 
Surgical 
wound 
ST1035 E1 - - WT WT WT WT TEM, SHV ≤1 ≤2 ≤0.5 
11 EK1108 09/11 OB/GYN 
Vaginal 
secretion
ST-U E1 - - WT WT WT WT SHV ≤1 ≤2 ≤0.5 
12 EK1206 11/12 Pulmonology Feces ST-U E3 Ib-cr B WT WT WT Lys TEM, ≥64 ≤2 1 
CTX-M-15 
13 EK1208 10/12 Emergency Blood ST-U E4 Ib-cr B WT WT WT WT
TEM, SHV, 
CTX-M-15 
≥64 ≤2 2 
14 EK1310 11/13 Cardiac surgery Urine E4 - - WT WT WT WT SHV 2 ≤2 ≤0.5 
15 EK1103 05/11 Digestive surgery Feces E4 Ib-cr B WT WT WT WT SHV, CTX-M-2 ≥64 ≤2 ≤0.5 
16 EK1104 04/11 Hematology Feces E5 Ib-cr B WT WT WT WT SHV ≥64 ≤2 1 
17 EK1107 09/11 Rheumatology Urine E5 - - WT WT WT WT SHV, CTX-M-2 ≤1 ≤2 ≤0.5 
18 EK1301 05/13 Neurology Urine E6 - - WT WT WT WT SHV ≤1 ≤2 1 
19 EK1303 08/13 Digestive surgery Feces 
 
E7 - S WT WT WT WT
SHV, CTX-M-1 
(non-CTX-M-15)
≥64 ≤2 1 
20 EK1306 09/13 OB/GYN 
Vaginal 
secretion  
E8 - - WT WT WT WT SHV ≤1 ≤2 ≤0.5 
21 EK1308 10/13 Nephrology Sputum E9 - S WT WT Ile WT TEM, CTX-M-9 ≥64 ≥16 2 
22 EK1309 10/13 Digestive surgery Urine 
 
E10 - S WT WT Ile WT
SHV, CTX-M-1 
(non-CTX-M-15)
≥64 ≤2 1 
23 EK1202 07/12 Digestive surgery Feces E11 Ib - WT WT WT WT SHV 32 ≥16 ≤0.5 
24 EK1203 08/12 Anesthesiology Feces E12 Ib - Tyr WT WT WT SHV ≥64 8 4 
25 EK1205 09/12 Pulmonology 
Tracheal 
aspirate  
E13 - - WT WT WT WT Not detected ≥64 ≤2 ≤0.5 
26 EK1101 02/11 Urology Urine E14 - S WT WT Ile WT TEM, CTX-M-9 ≥64 ≥16 1 
27 EK1102 03/11 Pulmonology Urine E15 - S WT WT WT WT TEM, SHV, ≥64 ≥16 1 
CTX-M-2 
28 EK1106 09/11 Digestive surgery Sputum E16 - - WT WT WT WT SHV ≤1 ≤2 ≤0.5 
29 EK1109 10/11 Rheumatology Urine E17 - - WT WT WT WT SHV, CTX-M-2 ≥64 ≤2 ≤0.5 
30 EK1111 12/11 Anesthesiology 
Tracheal 
aspirate 
  E18 - - WT WT WT WT SHV, CTX-M-2 ≥64 ≤2 ≤0.5 
 
*: Sequence typing was performed only in selected isolates.  
ST-U, undetermined ST. WT, wild type. OB/GYN, obstetrics and gynecology. CTX, cefotaxime. GEN, gentamicin. LVX, levofloxacin. 
 
  
Table 4. Fluoroquinolone susceptibility-related factors in CTX-M-15 or non-CTX-M-15 
isolates 
 
 CTX-M-15 (n=8) Non-CTX-M-15 
(n=22) 
P-value 
Levofloxacin resistance 5 (62.5) 2 (9.1) <0.01 
Number of QRDR mutations    
Three 5 (62.5) 2 (9.1) 
<0.01 
Less than three  3 (37.5) 20 (90.9) 
PMQR carriers    
aac(6’)-Ib-cr 8 (100.0) 3 (13.6) <0.01 
qnrB 2 (25.0) 2 (9.1) ns 
qnrS 0 (0.0) 5 (22.7) ns 
ns, not significant 
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